

About SK life science

SK Life Science, Inc., is a subsidiary of SK Biopharmaceuticals, Co., Ltd., focused on developing and bringing treatments for disorders of the central nervous system (CNS) to market. Both are a part of the global conglomerate SK Group, the second largest company in Korea¹. SK life science is growing quickly in the U.S., with headquarters in Fair Lawn, New Jersey.

SK life science has a pipeline of six products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The company's lead product is cenobamate, an investigational compound that is being studied as a potential treatment option for patients with epilepsy.

We are SK life science, a CNS-focused company

Values define us

SK life science is defined by our values and driven by the unmet needs of patients, HCPs, caregivers, and the CNS community—nothing else. From these needs our six core values were formed—they are more than words on a page; they are what you can expect from us.


Company values

- Empower excellence
- Be fully engaged
- Appreciate and recognize people
- Embody a pioneering spirit
- Always do the right thing
- Inspire happiness!



We believe there is more to life when you connect health with happiness.

Setting the stage for success in CNS



*Jazz Pharmaceuticals Inc. is a subsidiary of Jazz Pharmaceuticals plc.

On March 2, 2018, Jazz Pharmaceuticals plc announced that the US FDA accepted their New Drug Application for solriamfetol (JZP-110), an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Holding company structure



Leadership









Contact Us

General businessInfo@SKLifeScience.com

Strategic alliance and partnership opportunities
Partnerships@SKLifeScience.com

Media inquiries and PR
Media@SKLifeScienceInc.com